News About: Pharm. Industry
Daewoong seeks overseas expansion
Daewoong Pharm is boosting its overseas expansion drive, with the aim of becoming a leading CT contrast media manufacturer in Asia.
The company, which already established subsidiaries in the U.S., has received an ...
Local drugmakers urged to focus on new drug R&D projects
Domestic drug makers should focus on research and development of new drugs to survive in an anti-rebate environment, said C-TRI chairman Kim Wan-joo said.
He said they should pursue the knowledge-intensive industry...
Korean red ginseng effective for hyperlipemia
Korean red finseng is found to contain active ingredients that could improve hyperlipemia by lowering triglyceride level, according to a Korean scientist.
Dr. Kwak Li-sung of the Korean Ginseng Corporation, based ...
Who will be new KPMA head?
The pharmaceutical market is paying attention to board of directors of the Korea Pharmaceutical Manufacturers Association who have resumed efforts to find a new president of the association.
KPMA said its board has...
Bukwang beset by groundless M&A rumors
Bukwang Pharm is concerned over a drop in its stock prices due to rumors of its takeover by a multinational pharmaceutical firm.
The company has repeatedly denied any M&A scenarios, but its stock prices plummeted f...
Drugmakers support unified drug distribution system
Korean pharmaceutical firms are expressing their serious concerns over the government’s plan to scrap the unified drug distribution system from December 31, this year, according to pharmaceutical sources.
In a rece...
Dong-A to conduct phase I trial for new treatment of premature ejaculation
Dong-A Pharmaceutical Co. said on May 4 it will conduct its Phase I trial for a new medicine (codename: DA-8031) for the treatment of premature ejaculation (PE).
The company said the study will be conducted in Seou...
Dong-A Pharm acquires Samchully Pharm for 50 billion won
Dong-A Pharmaceutical Co., the top Korean drug maker, said on May 4 that it has struck a deal to take over Samchully Pharm for 50 billion won in its first acquisition of a domestic company.
“It will help us make in...
Green Cross to produce local tuberculosis vaccine
Green Cross, one of the nation's biggest pharmaceutical companies, said it will start production of its tuberculosis vaccine in 2014, which will be backed by the Korean government.
To this end, the company held a g...
Competition to be seen intensifying in hepatitis B drugs
Multination pharmaceutical companies, such as GlaxoSmithKline (GSK), BMS and Novartis, are stepping up their maketing in domestic hepatitis B treatment drug market valued at 100 billion won, which is forecast to becom...
